Safety of Gadoterate Meglumine (Gd-DOTA) as a Contrast Agent for Magnetic Resonance Imaging
Background: Safety is a primary concern with contrast agents used for MRI. If precautions could be taken before the repeated administration of gadolinium-based contrast media, then the awareness and management of adverse reactions would be more efficient.
Objectives: To assess the safety and efficacy of gadoterate meglumine (Gd-DOTA) [Magnescope® in Japan, Dotarem® in other countries], a gadolinium-based contrast agent, in patients undergoing imaging of the brain/spinal cord and/or trunk/limbs, and to identify factors associated with the onset of adverse reactions.
Methods: The study ran for 4 years and included 3444 cases. The study was conducted before it became known that gadolinium-based contrast agents could trigger the development of nephrogenic systemic fibrosis. Patients for whom the contrast agent was indicated and who underwent imaging of the brain/spinal cord and/or trunk/limbs by MRI were enrolled. There were 1300 inpatients who were followed up during hospitalization (for several days), and 2144 outpatients who were followed up for at least 2 hours on-site. After Gd-DOTA administration, 13 patient baseline characteristics were used to explore factors that might predict a greater likelihood of acute non-renal adverse reactions. The physician’s appraisal of the efficacy of Gd-DOTA was also assessed.
Results: A total of 40 adverse reactions were recorded in 32 patients, giving an overall incidence of adverse reactions of 0.93%. Gastrointestinal disorders were the most commonly reported adverse reactions (0.49%). Most adverse reactions reported were of mild intensity and no serious adverse reactions were reported. This study found that statistically significant risk factors for adverse reactions were general patient condition, liver disorder, kidney disorder, health complications, concomitant treatments, and Gd-DOTA dose (although the incidence of adverse reactions was not dose dependent). In the majority of cases (99.53%), the efficacy of Gd-DOTA was rated as ‘effective’ or ‘very effective’; only the presence of kidney disorder was associated with a significantly greater likelihood of Gd-DOTA inefficacy.
Conclusion: Overall, this postmarketing surveillance study did not reveal any untoward or unexpected findings concerning the safety or efficacy of Gd-DOTA. The low incidence of adverse reactions (<1%) and the absence of serious adverse reactions reported during the survey period showed that Gd-DOTA was very well tolerated. The use of Gd-DOTA as an MRI-enhancing contrast medium in the clinical practice setting appears to be safe and effective.
- Idee, JM, Port, M, Raynal, I (2006) Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 20: pp. 563-76 CrossRef
- Ruehm, SG, Goyen, M, Barkhausen, J (2001) Rapid magnetic resonance angiography for detection of atherosclerosis. Lancet 357: pp. 1086-91 CrossRef
- Claussen, C, Laniado, M, Schorner, W (1985) Gadolinium-DTPA in MR imaging of glioblastomas and intracranial metastases. AJNR Am J Neuroradiol 6: pp. 669-74
- Healy, ME, Hesselink, JR, Press, GA (1987) Increased detection of intracranial metastases with intravenous Gd-DTPA. Radiology 165: pp. 619-24
- Meaney, JF, Weg, JG, Chenevert, TL (1997) Diagnosis of pulmonary embolism with magnetic resonance angiography. N Engl J Med 336: pp. 1422-7 CrossRef
- Semelka, RC, Helmberger, TK (2001) Contrast agents for MR imaging of the liver. Radiology 218: pp. 27-38
- Thomsen, HS, Marckmann, P, Logager, VB (2007) Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents. Cancer Imaging 7: pp. 130-7 CrossRef
- Grobner, T (2006) Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephroge-nic systemic fibrosis?. Nephrol Dial Transplant 21: pp. 1104-8 CrossRef
- Kirchin, MA, Runge, VM (2003) Contrast agents for magnetic resonance imaging: safety update. Top Magn Reson Imaging 14: pp. 426-35 CrossRef
- Laurent, S, Elst, LV, Muller, RN (2006) Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging 1: pp. 128-37 CrossRef
- Port, M, Idee, JM, Medina, C (2008) Stability of gadolinium chelates and their biological consequences: new data and some comments. Br J Radiol 81: pp. 258-9 CrossRef
- Allard, M, Doucet, D, Kien, P (1988) Experimental study of DOTA-gadolinium: pharmacokinetics and pharmacologic properties. Invest Radiol 23: pp. S271-4 CrossRef
- Herborn, CU, Honold, E, Wolf, M (2007) Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA). Invest Radiol 42: pp. 58-62 CrossRef
- Oudkerk, M, Sijens, PE, Beek, EJ (1995) Safety and efficacy of dotarem (Gd-DOTA) versus magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system. Invest Radiol 30: pp. 75-8 CrossRef
- Brugieres, P, Gaston, A, Degryse, HR (1994) Randomised double blind trial of the safety and efficacy of two gadolinium complexes (Gd-DTPA and Gd-DOTA). Neuroradiology 36: pp. 27-30 CrossRef
- Beaudouin, E, Kanny, G, Blanloeil, Y (2003) Anaphylactic shock induced by gadoterate meglumine (DOTAREM). Eur Ann Allergy Clin Immunol 35: pp. 382-5
- Hasdenteufel, F, Luyasu, S, Renaudin, JM (2008) Anaphylactic shock after first exposure to gadoterate meglumine: two case reports documented by positive allergy assessment. J Allergy Clin Immunol 121: pp. 527-8 CrossRef
- DeHoratius, DM, Cowper, SE (2006) Nephrogenic systemic fibrosis: an emerging threat among renal patients. Semin Dial 19: pp. 191-4 CrossRef
- Cowper, SE (2003) Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 15: pp. 785-90 CrossRef
- Scheinfeld, N (2006) Nephrogenic fibrosing dermopathy: a comprehensive review for the dermatologist. Am J Clin Dermatol 7: pp. 237-47 CrossRef
- Cowper S. Nephrogenic fibrosing dermopathy [online]. Available from URL: http://www.icnfdr.org [Accessed 2010 Aug 27]
- Penfield, JG, Reilly, RF (2008) Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast agents?. Semin Dial 21: pp. 129-34 CrossRef
- Kimura, J, Ishiguchi, T, Matsuda, J (2005) Human comparative study of zinc and copper excretion via urine after administration of magnetic resonance imaging contrast agents. Radiat Med 23: pp. 322-6
- Tsushima, Y, Takahashi-Taketomi, A, Endo, K (2008) Nephrogenic systemic fibrosis in Japan: advisability of keeping the administered dose as low as possible. Radiology 247: pp. 915-6 CrossRef
- Safety of Gadoterate Meglumine (Gd-DOTA) as a Contrast Agent for Magnetic Resonance Imaging
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Drugs in R & D
Volume 10, Issue 3 , pp 133-145
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors